148 related articles for article (PubMed ID: 36799072)
1. Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis.
Torka P; Pederson LD; Knopp MV; Poon D; Zhang J; Kahl BS; Higley HR; Kelloff G; Friedberg JW; Schwartz LH; Wilson WH; Leonard JP; Bartlett NL; Schöder H; Ruppert AS
Cancer Med; 2023 Apr; 12(7):8211-8217. PubMed ID: 36799072
[TBL] [Abstract][Full Text] [Related]
2. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
[TBL] [Abstract][Full Text] [Related]
3. Interim FDG
Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Schöder H; Polley MC; Knopp MV; Hall N; Kostakoglu L; Zhang J; Higley HR; Kelloff G; Liu H; Zelenetz AD; Cheson BD; Wagner-Johnston N; Kahl BS; Friedberg JW; Hsi ED; Leonard JP; Schwartz LH; Wilson WH; Bartlett NL
Blood; 2020 Jun; 135(25):2224-2234. PubMed ID: 32232481
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.
Baek DW; Cho HJ; Kim JH; Sohn SK; Song GY; Ahn SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Jeong SY; Hong CM; Min JJ; Moon JH; Yang DH
In Vivo; 2020; 34(4):2127-2134. PubMed ID: 32606193
[TBL] [Abstract][Full Text] [Related]
6. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
[TBL] [Abstract][Full Text] [Related]
7. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL
Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
Lombion N; Robin P; Tempescul A; LE Roux PY; Schick U; Guillerm G; Ianotto JC; Berthou C; Salaün PY; Abgral R
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):402-409. PubMed ID: 35133099
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of
Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
[TBL] [Abstract][Full Text] [Related]
10. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.
Han EJ; O JH; Yoon H; Jung SE; Park G; Choi BO; Cho SG
Medicine (Baltimore); 2016 Sep; 95(39):e4983. PubMed ID: 27684851
[TBL] [Abstract][Full Text] [Related]
12. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
[TBL] [Abstract][Full Text] [Related]
13. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
[TBL] [Abstract][Full Text] [Related]
14. Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.
Kong Y; Qu L; Li Y; Liu D; Lv X; Han J
Medicine (Baltimore); 2016 Feb; 95(6):e2808. PubMed ID: 26871850
[TBL] [Abstract][Full Text] [Related]
15. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
[TBL] [Abstract][Full Text] [Related]
16. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
17.
Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
[TBL] [Abstract][Full Text] [Related]
18. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
20. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]